Previsión
| Comprar |
6 |
| Mantener |
5 |
| Vender |
2 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Spero Therapeutics receives $105 million from KKR unit, stock falls
Spero Therapeutics entered into a $105 million licensing and financing agreement with subsidiaries of Healthcare Royalty (KKR). HCRx will receive a portion of milestone and royalty payments from GSK’s Utebzi sales and will receive quarterly principal and interest payments from those receipts; after full repayment Spero will retain 35% of subsequent GSK payments. The funds will be used primarily to advance the phase-2 immunology candidate SP001, and Spero’s cash runway has been extended into the second half of 2029. The announcement pushed Spero’s stock down about 12% in premarket trading. » Más en de.investing.com
Spero Therapeutics secures $105 million financing from KKR unit for SP001 development
Spero Therapeutics agreed a non‑recourse royalty financing of $105 million with Healthcare Royalty (KKR), assigning part of future milestone and license payments from Utebzi sales. The funds will finance development of SP001, a monoclonal anti‑CD40L antibody intended for Phase 2; simultaneously Spero signed an exclusive licensing agreement with Innovent for SP001. Healthcare Royalty will receive quarterly principal and interest payments from GSK payments, and after repayment Spero will retain 35% of subsequent GSK payments; Spero thereby extends its cash runway into the second half of 2029 and reports a current ratio of 10.5. » Más en de.investing.com
Spero Therapeutics rises 16% after FDA approval for Utebzi
Shares of Spero Therapeutics climbed 16% after the FDA approved Utebzi, an oral carbapenem developed with GSK to treat complicated urinary tract infections in adults with limited oral options. Utebzi is the first oral carbapenem approved in the U.S.; the approval is based on the Phase III PIVOT-PO study, which showed noninferiority to intravenous imipenem‑cilastatin. The drug is expected to be available in the U.S. by the end of 2026; development was partially supported by BARDA. » Más en de.investing.com
Spero Therapeutics: board member Mahadevia resigns, SEC ends investigation
Dr. Ankit Mahadevia has resigned from the board of Spero Therapeutics with immediate effect and has also relinquished his committee and subsidiary mandates; the company cites other professional commitments for the resignation. Spero plans to engage Mahadevia as a consultant to continue supporting management. The U.S. securities regulator SEC said that, based on available information, it currently does not intend to pursue enforcement actions against Spero. In addition, the FDA’s re‑filing of the NDA for the oral carbapenem tebipenem HBr triggers an expected $25 million milestone payment to Spero in Q1 2026, subject to acceptance of the filing. » Más en de.investing.com
Spero Therapeutics beats Q2 expectations and stock rises
Spero Therapeutics reported Q2 2025 EPS of -$0.03 on revenue of $14.2 million, both well above expectations, and the stock rose double‑digit after the results. The company sharply reduced its net loss, extended its financing runway to 2028, and views Tebipenem HBr—after a successful Phase‑3 study—as on track for possible FDA approval in 2026. Challenges remain in the SPR720 program, and dependence on milestone payments continues to be a risk. » Más en de.investing.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasEn 2015, SPERO THERAP.INC. DL-,001 ya ha pagado 0,0534 € en dividendos. El último pago fue en octubre de 2015.
Datos financieros
En el último trimestre, SPERO THERAP.INC. DL-,001 tuvo unos ingresos de 0 € y un beneficio neto de -39,09 M €
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 0 | 100,00 % |
| Beneficio bruto | 0 | 100,00 % |
| Beneficio neto | -39,09 M | 521,43 % |
| EBITDA | -6,1 M | 2,27 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 46,41 M € |
Número de acciones | 58,26 M |
Máximo/mínimo de 52 semanas | 2,81 € - 0,79 € |
| Dividendos | No |
Beta | 1,56 |
Ratio P/E | -1,78 |
Ratio PEG | 0,00 |
Ratio P/B | 65,16 |
Ratio P/S | 1,28 |
Perfil de la empresa
Spero Therapeutics, Inc., una empresa biofarmacéutica en fase clínica, se dedica a identificar, desarrollar y comercializar tratamientos para infecciones bacterianas multirresistentes a fármacos (MDR) y enfermedades raras en Estados Unidos. Los candidatos a producto de la compañía incluyen el hidrobromuro de tebipenem pivoxilo (HBr), un antibiótico oral de la clase de los carbapenémicos para tratar infecciones complicadas del tracto urinario, incluida la pielonefritis en adultos; SPR206, un agente de acción directa administrado por vía intravenosa para tratar infecciones hospitalarias por bacterias Gram negativas multirresistentes; y SPR720, un antibiótico oral para el tratamiento de la enfermedad pulmonar por micobacterias no tuberculosas. La compañía tiene un acuerdo de licencia con Meiji Seika Pharma Co., Ltd. para apoyar el desarrollo de tebipenem HBr; un acuerdo de licencia con Everest Medicines para desarrollar, fabricar y comercializar SPR206 en China continental, Hong Kong, Macao, Taiwán, Corea del Sur y países del sudeste asiático; un acuerdo de colaboración con el Bill & Melinda Gates Medical Research Institute para desarrollar SPR720 para el tratamiento de infecciones pulmonares causadas por Mycobacterium tuberculosis; y un acuerdo de licencia con Vertex Pharmaceuticals Incorporated por patentes relacionadas con SPR720, así como con SPR719, un metabolito activo. La compañía fue fundada en 2013 y tiene su sede en Cambridge, Massachusetts.
| Nombre | SPERO THERAP.INC. DL-,001 |
| CEO | Esther Rajavelu |
| Sede | Cambridge,
ma Estados Unidos |
| Sitio web | |
| Sector | Materiales |
| Industria | Productos químicos |
| Salida a bolsa | 02/11/2017 |
| Empleados | 25 |
Deep Dive
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | SPRO |
Frankfurt | 2HA.F |
Düsseldorf | 2HA.DU |
München | 2HA.MU |